Table 4.

Association of peritransplant 1,25-dihydroxyvitamin-D3 levels dichotomized at 139.5 pM with TRM in discovery cohort and in joint replication cohorts.

	Peritransplant 1,25(OH)2D3 discovery data			Peritransplant 1,25(OH)2D3 joint replication data
	#at risk/#TRM	HR (95% CI)	P	#at risk/#TRM	HR (95% CI)	P
Unadjusted	143/23			365/66
Serum level ≤139.5 pMa		5.16 (2.12; 12.57)	<0.0005		3.51 (1.79; 6.88)	<0.0005
Adjusted I	128/21			364/66
Serum level ≤139.5 pMa		6.10 (2.24; 16.63)	<0.0005		3.30 (1.70; 6.44)	<0.0005
Age [yr]		1.08 (1.01; 1.15)	0.018		1.05 (1.02; 1.07)	0.001
Male sex		0.45 (0.19; 1.10)	0.081		0.92 (0.55; 1.54)	0.749
Unrelated donorb		0.99 (0.39; 2.54)	0.986		2.77 (1.25; 6.13)	0.012
Late tumor stagec		1.81 (0.073; 4.46)	0.197		1.03 (0.61; 1.72)	0.919
Adjusted II	128/21			361/63
Serum level ≤139.5 pMa		6.00 (2.16; 16.63)	0.001		3.31 (1.68; 6.53)	0.001
Age [yr]		1.05 (0.99; 1.12)	0.134		1.04 (1.01; 1.07)	0.006
Male sex		1.21 (0.44; 3.33)	0.712		0.95 (0.56; 1.61)	0.848
Unrelated donorb		0.82 (0.31; 2.21)	0.700		2.49 (1.11; 5.56)	0.026
Late tumor stagec		1.63 (0.63; 4.26)	0.317		0.99 (0.58; 1.69)	0.960
Severe aGvHDd		16.18 (5.56; 47.07)	<0.0005		4.96 (2.91; 8.47)	<0.0005

Shown are results from Cox proportional hazards models based on the 143 patients (23 TRM) of the discovery cohort and 365 patients (66 TRM) combining the three replication cohorts. Models for the joint replication cohorts are stratified by cohort. P values ≤0.05 are marked in bold.

TRM treatment-related mortality, 1,25(OH)2D3 1,25-dihydroxyvitamin-D3, HR hazard ratio, aGvHD acute Graft-versus-Host disease.

^a1,25(OH)2D3 level d-2–7 ≤/> cutoff 139.5 pM.

^bPatients with unrelated donors versus patients with sibling donors.

^cClassification according to EBMT risk score [50] late stage versus early/intermediate stage.

^dAny occurrence of aGvHD 3–4 [14] within 1 year after HSCT versus no occurrence of aGvHD 3–4.